HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 215 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $56,191,000 | +54.7% | 1,315,654 | -4.8% | 0.34% | -29.3% |
| Q3 2020 | $36,318,000 | +4.8% | 1,381,957 | +6.9% | 0.48% | +81.3% |
| Q2 2020 | $34,669,000 | -99.8% | 1,293,118 | +22.8% | 0.27% | +58.0% |
| Q1 2020 | $17,184,536,000 | -8.0% | 1,052,974 | 0.0% | 0.17% | +35.2% |
| Q4 2019 | $18,669,229,000 | +114210.7% | 1,052,974 | 0.0% | 0.12% | +9.6% |
| Q3 2019 | $16,332,000 | – | 1,052,974 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
| BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
| QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
| Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
| SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
| Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
| HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
| Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
| Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |